Introduction {#S0001}
============

The peroxisome proliferator-activated receptors (*PPARs*) are ligand-activated nuclear receptors (NRs) which play a pivotal role in the regulation of genes associated with a wide range of physiological processes. In the chromatin, *PPARs* are a heterodimer with retinoid X receptor (RXR) and play a role of specific *PPAR* elements (*PPRE*) response to ligand binding. Ligand binding triggers the conformational change of LBD, which promotes the dissociation or recruitment of transcription co-regulators, mainly through ligand-dependent activation function 2 (AF2). Besides, post-translational modifications can modulate the affinity of the receptor for co-regulators to determine whether the target gene is induced or suppressed.[@CIT0001]--[@CIT0003] There is no doubt that *PPARs* regulate genes involved in the metabolism of lipid and glucose. In addition, the *PPARs* are crucial to regulating some biological effects associated with vascular and inflammation feature.[@CIT0004]--[@CIT0006]

The PPARs also responding to the endogenous ligands including fatty acid metabolite and organic synthesis.[@CIT0007],[@CIT0008] *PPARα, PPAR β/δ* and *PPARγ* have been identified, which were significantly expressed in a tissue form. The most widely studied *PPARγ* isoforms are responsible for adipogenesis, glucose homeostasis, and regulation of lipid metabolism and gene transcription.[@CIT0009],[@CIT0010] *PPARγ* also has a critical role in insulin sensitization. Therefore, *PPARγ* is generally recognized as an ideal therapeutic measurement of diabetes and dyslipidemia. Thiazolidinediones (TZDs) such as rosiglitazone (RSG, [Figure 1](#F0001){ref-type="fig"}) and pioglitazone, are high-affinity ligands and full agonists of *PPARγ*, which have been successfully used to treat type II diabetes mellitus.[@CIT0011] TZDs have side effects in clinical application, we get the information of the *PPARγ* active mechanism and biological functions with the assistant of these synthetic ligands. TZDs as one type of *PPARγ* agonists have also been used as a potential drug candidate to develop effective and safe medicine.[@CIT0012]--[@CIT0014]Figure 1Chemical structures of piperine and RSG.

Natural products have been served as rich sources for the discovery and development of modern medicine. Piperine ([Figure 1](#F0001){ref-type="fig"}) isolated from the traditional Mongolian medicine of *piper longum* L., which is well known for its extensive biological activities. It has been reported that piperine attenuates the differentiation of fat cell, which down-regulating the activity and expression of *PPARγ*, prohibiting the process of adipogenesis[@CIT0015],[@CIT0016] and increases the bioavailability of many other drugs.[@CIT0017],[@CIT0018] However, piperine has an acutely toxic effect,[@CIT0019] its biological applications are limited due to the poor solubility in aqueous environments. According to related reports that piperoyl-amino conjugates have better biological activity than piperine,[@CIT0020] In addition, the results of piperine pharmacokinetic studies showed that after the piperine metabolism by the human, it retains methylenedioxy ring and conjugated double bonds while the piperidine ring is modified to form a propionic acid group. Such piperine derivatives may have the advantages of structural diversity, improved solubility, and reduced toxicity. Therefore, we wish to utilize amino acids and methylenedioxy ring as the alternative surrogates to couple with the piperine.

This study describes the synthesis and biological evaluation of piperine derivatives with the FP-based *PPARγ* ligand screening assay. Compound **2a** was identified as a potential *PPARγ* agonist with IC~50~ at 2.43 μM, which is 2 times more potent than the positive control Rosiglitazone with IC~50~ at 5.61μM. Molecular docking studies have shown that piperine derivative **2a** fitted nicely with the amino acid residues at the active site of the *PPARγ* complex and is consistent with the result of in vitro ligand assay.

Materials and Methods {#S0002}
=====================

Chemical Synthesis {#S0002-S2001}
------------------

### Synthesis of Piperic Acid {#S0002-S2001-S3001}

Piperine (64g, 219.9 mmol), KOH (113.5g, 17.9mmol) was refluxed with ethanol (1500mL) for 12h, the mixture was allowed to stand for cooling, suction filtration under reduced pressure, and the filter cake was washed with ethanol (95%) to pH=7, and filtered under reduced pressure to give crystals of brown piperic potassium salt. The crystal was dried to obtain the product. The piperic potassium salt was dissolved with water and then, gradually acidified with dilute hydrochloric acid, formed yellow precipitate, vacuum filtered, and washed with water (1400mL) and recrystallized from acetone to afford yellow crystalline compound.

### General Procedure for the Synthesis of Piperic Conjugates (2a-2j) {#S0002-S2001-S3002}

Pre-dried dichloromethane (DCM) was added to Piperic acid (2.18g, 10mmol), and then added thionyl chloride (73.8mmol, 14.4mL), the contents were reﬂuxed under nitrogen atmosphere for 2 hours. Removed the excess thionyl chloride under reduced pressure, and then got acid chloride of piperine. Amino acid ester hydrochloride (20mmol) in one portion to acid chloride of piperine in DCM; and Et~3~N in DCM under ice-cooling, stirred 2h at room temperature. Then added water (50 mL), washed the organic layer with water (2\*25mL), dried over with anhydrous sodium sulfate, concentrated to give the crude product. The crude product was dissolved in ethyl acetate as few as possible, and the yellow solids were obtained by slowly recrystallization with petroleum ether to get the pure compounds (**2a--2j**).

### General Procedure for the Synthesis of Piperic Conjugates (2k--2t) {#S0002-S2001-S3003}

Mixed neutral alumina (15g) with KF (10 g) in 200 mL of water for the preparation of KF-Al~2~O~3~. Then removed water at 50--60°C in a rotary evaporator, further dried this reagent in a vacuum oven for 12h. Added Piperic amino acid ester conjugates (1.65mmol, 0.5g) to KF-Al~2~O~3~(3.13mol, 40% KF) and then stirred this dry mixture at room temperature in a round bottom flask to ensure uniform mixing of solid support KF-Al~2~O~3~ with the substrate. Transfer the uniformly dispersed powder to a 50mL eggplant bottle and heat and stir at 50°C for 2h. Then the reaction mixture was added water (5mL), stirred for 5min and then filtered. Neutralized the filtrate by adding aqueous HCl and obtained the precipitate filtered, dried it, obtained the pure piperic amino acid conjugates compounds.

### General Procedure for the Synthesis of Derivatization of Bisphenol Piperic Amino Acid (Ester) Conjugates (3a--3e;3k--3o) {#S0002-S2001-S3004}

Dissolved piperic conjugates (2a-2e;2k-2o) with anhydrous DCM. Added BBr~3~ at −78 °C, stirred for 2h hours at 0°C, the solvent was removed under reduced pressure. The product was purified by column chromatography in DCM/MeOH (10:1) to get the pure compounds (**3a-3e;3k-3o**).

FP-Based *PPARγ* Ligand Screening Assay {#S0002-S2002}
---------------------------------------

We selected the *PPARγ* Ligand Screening Assay Kit, which provided a single-step assay to screen *PPARγ* ligands based on fluorescence polarization (FP).[@CIT0021],[@CIT0022] In this method, the ligand of *PPARγ* in conjunction with fluorescein and displacement probe. The fluorescent probes were replaced by *PPARγ* ligands, agonists and antagonists, resulting in the reduction of FP. Firstly, we prepared the assay cocktail and measured every ligand concentration in duplicate, covered the plate and used for 60--90 min at room temperature. Secondly, we read the data in the wavelengths of 470 nm and 530 nm, respectively. The results were calculated by FP. According to the kit protocol, we calculated IC50 with the mP-concentration displacement curve (Cayman).

Gene Expression Experiments to Activate *PPARγ* Assay {#S0002-S2003}
-----------------------------------------------------

### Cell Culture {#S0002-S2003-S3001}

Human normal hepatocytes (HL-7702\[L-02\]) purchased from the Biotechnology Research of Beijing BeNa Chuanglian in China. Quickly put the cryopreservation tube containing normal human hepatocytes into a 37 °C water bath and shake it constantly, so that the liquid in the tube will melt rapidly in 1--2 minutes. The cells suspension was transferred into the culture bottle adding CM 2--1 medium (90% RPMI-1640 + 10% FBS. RPMI-1640: 1640 medium, containing glutamine). And the cells were cultured in 5% CO~2~ incubator at 37 °C. The next day, the culture medium was changed for routine culture and passage. The cells grew well and were monolayer adherent. Depending on the number of cells, fresh culture medium should be replaced once every 2--3 days, and the passage should be 1:3 once every 4--5 days. When the cells grew to about 70% of the dish area, starvation culture was carried out. Then the cells were culture in RPMI-1640 medium without serum, which made the cells in a low nutritional state. It is for starvation culture. After 24 hours, the 100 μM compounds **2a**, **2t** or **3d** was added in the cultures. The "blank" indicated without drugs.

### Total RNA Extraction {#S0002-S2003-S3002}

Total RNAs of HL-7702\[L-02\] cells were isolated using the Trizol reagent kit (TRIzol™ Plus, Invitrogen, USA), following the manufacturer's instructions and described before. RNA integrity, purity, and concentration were detected by electrophoresis and the NanoDrop 2000C spectrophotometer (NanoDrop Technologies, Thermo Scientific™, USA).[@CIT0023] The integrity and purity of RNA samples met the requirements of RT-qPCR analysis.[@CIT0024] [<http://dx.doi.org/10.17504/protocols.io.qafdsbn>]{.ul}.

### Relative Quantitative Real-Time PCR {#S0002-S2003-S3003}

The cDNA synthesis was performed with 1 μg of total RNA as template in a 20 μL reaction mixture including 4 μmol/L of each primer using the TransScript^®^ One-Step gDNA Removal and cDNA Synthesis SuperMix Kit (TransGens, China) as described in the manufacture's protocol. The primers for RT-qPCR were designed, meeting the requirements with Tm values of 60°C and products shorter than 200bp. The pairs of primer *PPARγ*-RT-F (TATCGACCAGCTGAATCCAGAG) and *PPARγ*-RT-R (GGGGGTGATGTGTTTGAACTTG); Human-actin-RT-F (CTCCATCCTGGCCTCGCTGT) and Human-actin-RT-R (GCTGTCACCTTCACCGTTCC) were used in RT-qPCR assay. The RT-qPCR assay was performed using the PerfectStart TM Green qPCR SuperMix kit (TransGens, China). And the Light Cycler 480 II Real-Time PCR System (Roche, Switzerland) was used as a quantitative analysis detector. The RT-qPCR procedure used default procedure (95 °C for 30 s, 45 cycles of 95°C for 10 s, 60 °C for 20 s) and the melting curves were performed immediately as described previously.[@CIT0023] The CT value of each reaction can be given automatically. The relative standard curve was made by template concentration (X-axis) and threshold cycles (Y-axis). Amplification efficiency (E) was calculated from equation 1, and gene dose was determined from equation 2, as described previously. Then, the target gene relative expressions were calculated by formula 2^(-ΔΔCt)^.[@CIT0024] The β-actin gene was the reference gene. The expression level of target genes was normalized to this reference gene. The final data came from three test repetitions, each with three technical repetitions.

Molecular Docking {#S0002-S2004}
-----------------

We used the crystal structure (PDB: 4EMA) of the *PPARγ* docking template combined with **RSG**. We used AutoDock 4.2.6 docking compounds **2a, 2t** and **3d** into the ligand-binding domain.[@CIT0025] Implemented AutodockTools 1.5.6 to build the autogrid box. Based on the known ligand, Set the grid center, and the grid contained 14×8×44 autogrid points, which is 0.375Å spacing. In the population, the number of individuals was 150, the maximum number of energy evaluations was 25 million and the generations were 27,000, respectively.

Results and Discussion {#S0003}
======================

Chemistry {#S0003-S2001}
---------

Following the synthetic scheme shown in [Scheme 1](#SCH0001), a total of 30 piperine derivatives were synthesized (see [[Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=238245.docx)]{.ul}). The basic skeleton of piperine consists of methylenedioxyphenyl (MDP) moiety, basic six-membered piperidine moiety attached to side-chain via an amide and linkage side-chain which consists of double bonds. This study aimed to establish SAR focusing on the side chain of piperine. A series of piperine derives shown in [Table 1](#T0001){ref-type="table"}. Converted piperine into acid by hydrolysis used ethanolic KOH. Converted the acid into acid chloride used thionyl chloride, and then followed by condensation with the amine moiety of amino acid in dichloromethane. Basically, the part of piperine's piperidine moiety was replaced by different amino acid esters and substituted aniline to obtain compounds **2a--2t**. Boron tribromide can be used for the demethylation of aryl methyl ethers in the presence of many functional groups without affecting these, it does not affect the cleavage of methylenedioxy groups. Halogenation was done with boron tribromide to give piperine catechol **3a-3e, 3k-3o**. Scheme 1Reagents and conditions.**Notes:** (i) KOH, ethanol, reflux, 12h; HCl (ii) SOCl~2~, DCM, reflux, 12h (iii) DCM, (**2a-2j**), Et~3~N, rt, **2h** (iv) KF- Al2O3, 50°C, **2h** (v) BBr~3~, DCM, -78°C, **2h**.Table 1Synthesis of Piperine DerivativesCompoundsRCompoundsR'**2a**![](DDDT-14-2069-i0001.jpg){#ILF0001}**2k**![](DDDT-14-2069-i0002.jpg){#ILF0002}**2b**![](DDDT-14-2069-i0003.jpg){#ILF0003}**2L**![](DDDT-14-2069-i0004.jpg){#ILF0004}**2c**![](DDDT-14-2069-i0005.jpg){#ILF0005}**2m**![](DDDT-14-2069-i0006.jpg){#ILF0006}**2d**![](DDDT-14-2069-i0007.jpg){#ILF0007}**2n**![](DDDT-14-2069-i0008.jpg){#ILF0008}**2e**![](DDDT-14-2069-i0009.jpg){#ILF0009}**2o**![](DDDT-14-2069-i0010.jpg){#ILF0010}**2f**![](DDDT-14-2069-i0011.jpg){#ILF0011}**2p**![](DDDT-14-2069-i0012.jpg){#ILF0012}**2g**![](DDDT-14-2069-i0013.jpg){#ILF0013}**2q**![](DDDT-14-2069-i0014.jpg){#ILF0014}**2h**![](DDDT-14-2069-i0015.jpg){#ILF0015}**2r**![](DDDT-14-2069-i0016.jpg){#ILF0016}**2i**![](DDDT-14-2069-i0017.jpg){#ILF0017}**2s**![](DDDT-14-2069-i0018.jpg){#ILF0018}**2j**![](DDDT-14-2069-i0019.jpg){#ILF0019}**2t**![](DDDT-14-2069-i0020.jpg){#ILF0020}**3a**![](DDDT-14-2069-i0021.jpg){#ILF0021}**3k**![](DDDT-14-2069-i0022.jpg){#ILF0022}**3b**![](DDDT-14-2069-i0023.jpg){#ILF0023}**3L**![](DDDT-14-2069-i0024.jpg){#ILF0024}**3c**![](DDDT-14-2069-i0025.jpg){#ILF0025}**3m**![](DDDT-14-2069-i0026.jpg){#ILF0026}**3d**![](DDDT-14-2069-i0027.jpg){#ILF0027}**3n**![](DDDT-14-2069-i0028.jpg){#ILF0028}**3e**![](DDDT-14-2069-i0029.jpg){#ILF0029}**3o**![](DDDT-14-2069-i0030.jpg){#ILF0030}

FP-Based *PPARγ* Ligand Screening Assay {#S0003-S2002}
---------------------------------------

We used a convenient FP-based *PPARγ* ligand screening assay to assess the agonistic potency of 30 piperine derivatives.[@CIT0026],[@CIT0027] We chose RSG as a *PPARγ* agonist as a positive control. The addition of large amounts of a *PPARγ* ligand would result in a larger reduction in the MP value of the well. So, plotting mP vs ligand concentration allowed the construction of an IC~50~ curve with a broad dynamic range. As shown in [Figure 2](#F0002){ref-type="fig"}, thirteen compounds (**2a, 2e, 2i, 2m, 2n, 2p, 2q, 2r, 2s, 2t, 3a, 3b, 3c, 3d**) were found to exhibit potent agonistic activity. As shown in [Figure 3](#F0003){ref-type="fig"}, the MP values of three compounds (**2a, 2t, 3d**) decreased significantly with the increasing of the logarithm of the concentration, and this trend was consistent with the positive control. However, the MP values of negative control (DMSO) were consistent with the change of concentration. As shown in [Table 2](#T0002){ref-type="table"}, the compound **2t** (IC~50~=1.03 μM) showed the most potent effects of FP, the compound **2a** (IC~50~=2.43 μM) showed the remarkable agonistic activity on *PPARγ*, they were both more potent than **RSG** (IC~50~=5.61 μM) and **piperine**(IC~50~=18.35 μM). Besides, the compound **3d** (IC~50~=79.32μM) showed moderate agonistic activity on *PPARγ*. Among the 30 small-molecule piperine derivatives (**2a-2t, 3a-3e** and **3k-3o**), piperine derivatives exhibited biological activity better than piperine. Especially, we founded the group of the amino acid-modified piperine contribute the most to the agonist potency **(2t \> 2a\> 3d)**. Compounds **2t** and **2a** are being investigated in vivo and results will be reported separately.Table 2IC~50~s of Piperine Derivatives in FP-Based *PPARγ* Ligand Screening AssayCompoundsChemical StructureIC~50~(µM)**2a**![](DDDT-14-2069-i0031.jpg){#ILF0031}2.43**2t**![](DDDT-14-2069-i0032.jpg){#ILF0032}1.03**3d**![](DDDT-14-2069-i0033.jpg){#ILF0033}79.32**Piperine**![](DDDT-14-2069-i0034.jpg){#ILF0034}18.35**RSG**![](DDDT-14-2069-i0035.jpg){#ILF0035}5.61 Figure 2FP-based *PPARγ* ligand screening assay of piperine derivatives.Figure 3Compounds **2a, 2t, 3d** showed potent effects of FP comparable to RSG.

The Compounds 2a, 2t, and 3d Can Activate the Gene Expression of *PPARγ* {#S0003-S2003}
------------------------------------------------------------------------

We cultured human normal hepatocytes, which were treated with 100 μM compounds **2a, 2t** or **3d**. And then the levels of *PPARγ* gene expression were determined. So as to show whether the compounds could activate or inhibit the expression of *PPARγ*. The human hepatocytes HL-7702\[L-02\] cells were cultured and treated with compounds **2a, 2t** or **3d** as described in the method section. We found that the relative expression of the *PPARγ* activity increased by 11.8, 1.9 and 7.0 times in compounds **2a, 2t** and **3d**, respectively, compared with the "blank" ([Figure 4](#F0004){ref-type="fig"}). These results indicated that compounds **2a, 2t**, and **3d** could activate *PPARγ*, in which three compounds, compound **2a** activation was the most significant.Figure 4The relative expression level of PPARγ in compound of **2a**, **2t** and **3d**.**Notes:** The values are the average of three experiments. The standard error bars are as indicated. The significance of discrepancy between data by single factor analysis of variance. The "\*" showed significant differences between blank and compounds, "\*"*p*-value\<0.05; "\*\*"*p*-value\<0.001.

Molecular Docking {#S0003-S2004}
-----------------

Firstly, according to the *PPARγ* complex's X-ray structure, the binding mode of RSG has been analyzed. The TZD of RSG and the three amino acid residues (His323, Ser289, and Tyr473) forms an H-bonding interaction. The RSG's hydrophobic tail interacts with the residues of Ile341, Val339, Phe363, Leu353, Phe368, Met364 and Leu330. So, we have chosen low binding energy and a similar binding mode for the study to dock poses. In [Table 3](#T0003){ref-type="table"}, the in vitro agonistic activity showed good correlations with the molecular properties. The potent compounds proved useful for examining the piperine derivatives because they displayed high values of tPSA and LogP, we did the experiment to identify the complex for the docking study. The binding energy of RSG was at −5.3 kcal/mol, while that of **2a** was at −1.2 kcal/mol. This discrepancy showed that the chemical structure of piperine derivative and RSG play a significant role in the binding pocket and it is conceivable that the receptor was differentially sensitized by the binding moieties of RSG and piperine. There was a good correlation between piperine derivatives with similar chemical structures. But, among the three agonists (**2a, 2t**, and **3d**), compound, **2a** exhibited the highest *PPARγ* activity and the highest binding energy. The **2a** interacted with Ser289's residues to form the *PPARγ* active sites' hydrogen bonds and its hydrophobic tail was encompassed from Val339, Leu340, Ile341, Try327, Leu330 by a surface formed. The **2t** interacted with residues of Tyr473, His449, Ser342 to form the *PPARγ* active sites' hydrogen bonds. The **3d** interacted with residues of Ser289 to form hydrogen bonds to the *PPARγ* active sites His449. ([Figure 5A](#F0005){ref-type="fig"}--[E](#F0005){ref-type="fig"}).Table 3The Molecular Properties and Binding Energy of Selected Piperine DerivativesCompoundsMolecular PropertiesBinding Energy kcal/moltPSALogP**2a**73.861.83−1.2**2t**96.892.79−2.4**3d**95.61.61−2.2**Piperine**38.772.78−6.5**RSG**71.003.21−5.3 Figure 5The binding modes of agonists with *PPARγ.***Notes:** H-binding interactions of RSG and other agonists were shown in yellow dotted line, respectively. (**A**) **2a**, (**B**) **2t**, (**C**) **3d**, (**D**) piperine, (**E**) RSG.

Conclusion {#S0004}
==========

*PPARγ* is considered as a therapeutic target for the treatment of diabetes and dyslipidemia, which modulates the transcription of genes responsible for glucose homeostasis, adipose differentiation, and lipid metabolism. In this study, we synthesized 30 piperine derivatives and evaluated with quick FP-based *PPARγ* ligand screening assay to agonistic activity with an easy. A preliminary structure-activity relationship was established. Among the derivatives tested, ligand **2a** and **2t** exhibited potent *PPARγ* agonistic activity than **RSG** and piperine. By test the gene expression of *PPARγ* in human normal hepatocytes, we found that compound **2a, 2t**, and **3d** could activate *PPARγ*, compound **2a** activation was the most significant. Molecular docking studies indicated that the piperine derivative **2a** stably interacts with the amino acid residues of the *PPARγ* complex active site, which is consistent with the results of the in vitro *PPARγ* ligand screening assay. The compound of **2a**'s further chemical modifications and in vivo evaluation is in progress.
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